Tamoxifen: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
No edit summary |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| Line 9: | Line 9: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups. | |notes=While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups. | ||
| | |treatment_category=Repurposed Drugs | ||
|links= | |links= | ||
|toxicity_level=3.5 | |toxicity_level=3.5 | ||
|toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage. | |toxicity_explanation=Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage. | ||
}} | }} | ||
Latest revision as of 10:24, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Tamoxifen |
| FDA Approval | Yes (for breast cancer treatment) |
| Used for | Investigational use in glioblastoma (GBM) due to its inhibition of protein kinase C |
| Clinical Trial Phase | Phase II clinical trials and retrospective studies for GBM |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain |
| OS without | Not specified |
| OS with | Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics |
| PFS without | Not specified |
| PFS with | In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 3.5 |
| Toxicity Explanation | Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage. |
Notes: While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.
From Ben Williams Book: Not specified
Loading comments...
